CTLA4 and melanoma: Combination of anti-PD1 and anti-CTLA-4 inhibitors demonstrated superior response rates compared with monotherapy in advanced melanoma [39], as well as in advanced NSCLC in a few early phase trials, with ongoing cohort expansion and phase III trials for confirmation of activity pending [40, 41].